Synthetic lethality, defined as the synergistic lethality resulting from the co-occurrence of two genetic alterations, represents a promising therapeutic approach for addressing cancers with otherwise difficult molecular targets. This concept is being actively explored to identify novel cancer vulnerabilities, with multiple strategies progressing to advanced stages of preclinical and clinical evaluation.
A recent review by researchers at MD Anderson highlights the potential of leveraging synthetic lethality in cancer drug discovery and emphasizes the importance of robust predictive biomarkers in guiding therapeutic development.
Insights or updates on research groups applying these principles in drug discovery would be highly valuable.
Ngoi, Natalie YL, et al. "Synthetic lethal strategies for the development of cancer therapeutics." Nature Reviews Clinical Oncology (2024): 1-19
------------------------------
Sudip Das, MPharm, PhD
Distinguished Faculty, Butler University
Professor of Pharmaceutics & Drug Delivery
4600 Sunset Avenue, Indianapolis, IN 46208-3485
E-mail:
[email protected]Webpage:
https://research.butler.edu/nanomedicine/LinkedIn:
http://www.linkedin.com/in/sudipkdasDisclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------